Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Gynakologisch-Geburtshilfliche Rundschau
|
January 1, 1993
[Initial experience with preoperative use of erythropoietin for prevention of homologous blood transfusion]
A Prechtl, W Loos, H Graeff
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 24, 2016
Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study
U Reinhold, I Hadshiew, A Melzer, et al.
MMW Fortschritte Der Medizin
|
July 4, 2016
[Not Available]
A M Kaufmann, R Schmidt-Ott, A Prechtl
MMW Fortschritte Der Medizin
|
May 24, 2011
[Novel adjuvants in vaccine development]
A M Kaufmann, R Schmidt-Ott, A Prechtl
Fortschritte Der Medizin
|
October 20, 1994
[Blood transfusion in surgical gynecology. Strategies for preventing homologous blood transfusion]
W Loos, W Kuhn, A Prechtl, et al.
Acta Neurologica Scandinavica
|
September 12, 2014
Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability
M Freidel, K Tiel-Wilck, H Schreiber, et al.
Cancer Research
|
May 15, 1994
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
F Jänicke, L Pache, M Schmitt, et al.
Journal of the National Cancer Institute
|
June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke, A Prechtl, C Thomssen, et al.
The International Journal of Biological Markers
|
April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
A Prechtl, N Harbeck, C Thomssen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Gynakologisch-Geburtshilfliche Rundschau
|
January 1, 1993
[Initial experience with preoperative use of erythropoietin for prevention of homologous blood transfusion]
A Prechtl, W Loos, H Graeff
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 24, 2016
Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study
U Reinhold, I Hadshiew, A Melzer, et al.
MMW Fortschritte Der Medizin
|
July 4, 2016
[Not Available]
A M Kaufmann, R Schmidt-Ott, A Prechtl
MMW Fortschritte Der Medizin
|
May 24, 2011
[Novel adjuvants in vaccine development]
A M Kaufmann, R Schmidt-Ott, A Prechtl
Fortschritte Der Medizin
|
October 20, 1994
[Blood transfusion in surgical gynecology. Strategies for preventing homologous blood transfusion]
W Loos, W Kuhn, A Prechtl, et al.
Acta Neurologica Scandinavica
|
September 12, 2014
Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability
M Freidel, K Tiel-Wilck, H Schreiber, et al.
Cancer Research
|
May 15, 1994
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
F Jänicke, L Pache, M Schmitt, et al.
Journal of the National Cancer Institute
|
June 21, 2001
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke, A Prechtl, C Thomssen, et al.
The International Journal of Biological Markers
|
April 14, 2000
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
A Prechtl, N Harbeck, C Thomssen, et al.
Page
of 1